Novel approach shows promise for cystic fibrosis

An investigational drug targeting a defective protein that causes cystic fibrosis has been shown to improve lung function in a small study of CF patients. The drug, VX-770, appeared to improve function of what is known as CFTR -- the faulty protein responsible for CF. It is among the first compounds being developed for CF that specifically targets the root cause of cystic fibrosis.

Read the whole article on Science Daily

More from Science Daily